2026-W46 · Nov 9–Nov 15 · Company · Profile · published
The Cooper Companies, Inc. company profile · business segments · history · financial snapshot · S&P 500 rank #473 · The Cooper Companies公司業務歷史財務與標普500地位
SNAPSHOT
| Ticker | COO |
| Company | The Cooper Companies, Inc. |
| GICS sector / industry | Health Care (XLV) / Health Care Supplies |
| S&P 500 rank (by weight) | #473 · 0.02% (Nov 5, 2026) |
| Sector rank | #54 of 60 in Health Care (Nov 5, 2026) |
| Headquarters | San Ramon, California, U.S. |
| Founded | 1958 |
| CEO | Walter M. Rosebrough Jr. (Interim Executive Chair, overseeing day-to-day operations; permanent CEO search underway) |
| Employees | More than 15,000 (as of October 31, 2025) |
| Market cap | $12.31B (Nov 5, 2026) |
| SEC filings | EDGAR — CIK 711404 |
WHAT IT DOES
The Cooper Companies, Inc., branded CooperCompanies, is a San Ramon, California-based global medical device company with two businesses. CooperVision develops, manufactures and markets soft contact lenses — daily disposables, two-week and monthly lenses for myopia, astigmatism and presbyopia, plus the MiSight 1 day lens, the first product approved by the U.S. FDA to slow the progression of myopia in children aged 8–12 at the start of treatment. CooperSurgical serves fertility and women's health: products and services for fertility clinics (IVF devices, genetic testing, donor egg and sperm banking, cryostorage) and medical devices used in offices, surgery centres and hospitals, including contraception and labour and delivery products. Fiscal 2025 revenue was $4.09B, split $2.74B CooperVision and $1.35B CooperSurgical, with manufacturing concentrated in the Americas, Europe and Costa Rica.
BUSINESS SEGMENTS
| CooperVision | One of the world's largest soft contact lens makers: single-use, two-week and monthly lenses in silicone hydrogel and other materials, including toric lenses for astigmatism, multifocal lenses for presbyopia, the MiSight 1 day myopia-management lens for children, and ortho-k and scleral specialty lenses, sold to wearers via eye care practitioners. FY2025 net sales $2,743.8M. |
| CooperSurgical | Fertility and women's health products and services: more than 600 offerings including IVF and fertility clinic products and genomic services, egg and sperm donation and cryostorage (including cord blood and tissue storage), contraception, and medical devices for offices, surgery centres and hospitals. FY2025 net sales $1,348.6M (office and surgical $824.0M; fertility $524.6M). |
HISTORY
| Year | Milestone |
|---|---|
| 1958 | Parker Montgomery buys Martin H. Smith Co., the origin of today's company; it becomes Cooper, Tinsley Laboratories in 1961 and Cooper Laboratories in 1967. |
| 1972 | Cooper enters the contact lens business by acquiring British lens maker GlobalVision. |
| 1987 | The company is renamed The Cooper Companies and is later restructured around CooperVision and CooperSurgical (the latter formed as a business unit in 1990). |
| 2014 | CooperVision acquires UK contact lens maker Sauflon Pharmaceuticals for about $1.2B, adding Clariti lenses and daily-disposable capacity. |
| 2021 | CooperSurgical acquires Generate Life Sciences for $1.6B in December 2021, building a leading fertility services platform; an $875M acquisition of Cook Medical's reproductive health business was announced in February 2022 but was terminated in August 2023 after FTC scrutiny and never closed. |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT
| Total revenue | $4.09B (FY2025 revenue) |
| Operating income | $682.9M (FY2025 operating income) |
| Net income | $374.9M (FY2025 net income) |
| Diluted EPS | $1.87 (FY2025 diluted EPS) |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
Cooper Companies is a small-weight Health Care constituent: rank #473 by weight at 0.02% as of Nov 5, 2026, and #54 of 60 in Health Care. It is the index's purest large-scale exposure to the global contact lens market, paired with a fertility and women's health device business built through acquisitions.
SOURCES & METHODOLOGY
| Financials, segments, headquarters | The Cooper Companies, Inc. fiscal 2025 Form 10-K via SEC EDGAR (see Financial Snapshot note); headquarters, CEO and history via the Form 10-K and Wikipedia company profile |
| Index weight & ranks | Slickcharts S&P 500 weights, fetched Nov 5, 2026; sector membership per Wikipedia List of S&P 500 companies (GICS) |
| Market cap | $12.31B (Slickcharts, Nov 5, 2026) |
| Logo | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. |
| Chart | SPXSet chart library, monthly bars, compiled from Yahoo public information. |
Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com
FINANCIALS
公司快照
| 股票代號 | COO |
| 公司 | The Cooper Companies, Inc.(The Cooper Companies) |
| GICS 板塊/行業 | 健康護理(XLV)/醫療用品 |
| 標普500排名(按權重) | #473 · 0.02%(Nov 5, 2026) |
| 板塊內排名 | 健康護理板塊 #54(共 60 家)(Nov 5, 2026) |
| 總部 | 美國加利福尼亞州聖拉蒙 |
| 成立 | 1958年 |
| 執行長 | Walter M. Rosebrough Jr.(臨時執行主席,主持日常營運;常任行政總裁遴選進行中) |
| 員工 | 逾15,000人(截至2025年10月31日) |
| 市值 | $12.31B(Nov 5, 2026) |
| SEC 申報 | EDGAR — CIK 711404 |
業務概覽
The Cooper Companies, Inc.(品牌名稱 CooperCompanies)是一家總部位於加利福尼亞州聖拉蒙的全球醫療器械公司,旗下有兩項業務。CooperVision 開發、製造及銷售軟性隱形眼鏡 — 包括日拋、兩星期及月拋鏡片,矯正近視、散光及老花,另有 MiSight 1 day 鏡片,是首款獲美國食品藥物管理局批准、用於減緩8至12歲開始治療兒童近視加深的產品。 CooperSurgical 服務生育及女性健康市場:為生育診所提供產品及服務(體外受精器械、基因檢測、捐贈卵子及精子儲存、冷凍保存),以及供診所、手術中心及醫院使用的醫療器械,包括避孕及分娩產品。2025財年收入40.92億美元,其中 CooperVision 佔27.44億美元、CooperSurgical 佔13.49億美元,生產主要集中於美洲、歐洲及哥斯達黎加。
業務板塊
| CooperVision(視力護理) | 全球最大軟性隱形眼鏡製造商之一:以矽水凝膠及其他物料製造即棄、兩星期及月拋鏡片,包括矯正散光的散光鏡片、矯正老花的漸進鏡片、兒童近視管理鏡片 MiSight 1 day,以及角膜塑形及鞏膜等特殊鏡片,經眼科護理專業人員售予佩戴者。2025財年淨銷售額27.44億美元(2,743.8百萬美元)。 |
| CooperSurgical(外科及生育) | 生育及女性健康產品和服務:逾600項產品及服務,包括體外受精及生育診所產品和基因服務、卵子及精子捐贈和冷凍保存(包括臍帶血及臍帶組織儲存)、避孕產品,以及供診所、手術中心及醫院使用的醫療器械。2025財年淨銷售額13.49億美元(1,348.6百萬美元)(診所及外科8.24億美元;生育5.25億美元)。 |
歷史
| 年份 | 里程碑 |
|---|---|
| 1958 | Parker Montgomery 購入 Martin H. Smith Co.,成為今日公司的起源;公司於1961年改稱 Cooper, Tinsley Laboratories,1967年再改稱 Cooper Laboratories。 |
| 1972 | Cooper 收購英國鏡片製造商 GlobalVision,進軍隱形眼鏡業務。 |
| 1987 | 公司更名為 The Cooper Companies,其後圍繞 CooperVision 及 CooperSurgical 重組(後者於1990年成為業務部門)。 |
| 2014 | CooperVision 以約12億美元收購英國隱形眼鏡製造商 Sauflon Pharmaceuticals,加入 Clariti 鏡片及日拋鏡片產能。 |
| 2021 | CooperSurgical 於2021年12月以16億美元收購 Generate Life Sciences,建立領先的生育服務平台;原定以8.75億美元收購 Cook Medical 生殖健康業務的交易於2022年2月公布,惟於2023年8月經聯邦貿易委員會審查後終止,從未交割。 |
競爭地位
財務快照
| 總收入 | 40.92 億美元(2025 財年收入) |
| 營業利潤 | 6.83 億美元(2025 財年營業利潤) |
| 淨利潤 | 3.75 億美元(2025 財年淨利潤) |
| 稀釋 EPS | 1.87 美元(2025 財年稀釋 EPS) |
主要風險
對標普500的重要性
Cooper Companies 是健康護理股中權重較小的成份股:截至2026年11月5日,按權重排名第473位,權重0.02%,在健康護理板塊60隻股票中排第54位。它是指數內對全球隱形眼鏡市場最大規模的純粹敞口,並配以透過收購建立的生育及女性健康器械業務。
來源與方法
| 財務、板塊、總部 | The Cooper Companies, Inc. 2025 財年 Form 10-K,經 SEC EDGAR 取得(見財務摘要附註);總部、行政總裁及歷史資料來自 Form 10-K 及維基百科公司條目 |
| 指數權重與排名 | Slickcharts 標普 500 權重,Nov 5, 2026 抓取;板塊歸屬按維基百科標普 500 成分股名單(GICS) |
| 市值 | $12.31B(Slickcharts,Nov 5, 2026) |
| Logo | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。 |
| 股價圖 | SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。 |
來源:Yahoo Finance 月線(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-11-04 14:30 · updated 2026-11-14 23:11 · rev 9